{"gene":"TUBA4A","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":2014,"finding":"TUBA4A missense mutations found in familial ALS patients destabilize the microtubule network and diminish its repolymerization capability, as demonstrated by functional microtubule repolymerization assays in patient-derived cells.","method":"Exome-wide rare variant burden analysis plus microtubule repolymerization functional assay","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — direct functional assay (repolymerization) with multiple ALS-linked variants; replicated in independent cohort; foundational discovery paper with 292 citations","pmids":["25374358"],"is_preprint":false},{"year":2018,"finding":"Excess TBCB (tubulin-folding cofactor B), caused by downregulation of microRNA-1825, leads to depolymerization and degradation of TUBA4A protein. This miR-1825/TBCB/TUBA4A pathway was confirmed in ALS brain cortex tissue and knockdown of the TUBA4A orthologue in zebrafish caused motor axon defects, establishing TBCB as a negative regulator of TUBA4A stability.","method":"Combined transcriptomic and proteomic analysis, in vivo zebrafish knockdown, Western blotting of patient brain tissue","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (proteomics, in vivo model, patient tissue validation); identifies upstream regulatory mechanism","pmids":["30030593"],"is_preprint":false},{"year":2021,"finding":"A TUBA4A variant associated with familial FTD results in decreased TUBA4A protein abundance and disrupted α-tubulin function as shown by microtubule repolymerization assay; FTD-associated variants appear more localized to the N-terminus compared to ALS variants, suggesting distinct pathogenic mechanisms.","method":"Microtubule repolymerization assay, immunoblotting, immunohistochemistry","journal":"Neurology. Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — direct repolymerization functional assay; single lab, moderate mechanistic depth","pmids":["34169147"],"is_preprint":false},{"year":2022,"finding":"An N-terminal frameshift mutation in TUBA4A (p.Arg64Glyfs*90) produces no detectable truncated protein and leads to reduced total TUBA4A mRNA and protein levels, supporting haploinsufficiency as a pathogenic mechanism for N-terminal TUBA4A mutations; in contrast, C-terminal TUBA4A mutations are proposed to act via dominant-negative disruption of the microtubule network.","method":"qPCR, immunohistochemistry, Western blotting of patient brain tissue","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2-3 — patient tissue analysis with multiple molecular methods establishing mechanistic distinction between N- and C-terminal mutations; single case study","pmids":["35327632"],"is_preprint":false},{"year":2024,"finding":"Knockdown of the zebrafish TUBA4A orthologue induced motor axonopathy and disturbed motor behavior in a dose-dependent manner; both phenotypes were rescued by human wild-type TUBA4A mRNA. TUBA4A loss-of-function also caused significant changes in tubulin post-translational modifications, including reduced acetylation, detyrosination, and polyglutamylation.","method":"Antisense morpholino knockdown in zebrafish embryos, motor axon visualization, touch-evoked escape response assay, mRNA rescue experiment","journal":"Frontiers in cellular neuroscience","confidence":"High","confidence_rationale":"Tier 2 — in vivo loss-of-function with dose-dependence, mRNA rescue, and downstream PTM analysis; multiple orthogonal readouts","pmids":["38463699"],"is_preprint":false},{"year":2023,"finding":"In silico molecular dynamics modeling of ALS-linked TUBA4A mutations predicts that specific mutations (e.g., K430N, R215C, W407X) impair GTP binding and tubulin polymerization, while others (R320C, K430N) significantly increase aggregation propensity of the TUBA4A α-chain, suggesting that failure to form a stable tubulin heterocomplex is a key pathogenic mechanism.","method":"Molecular dynamics simulation, molecular docking","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no experimental validation","pmids":["36747013"],"is_preprint":false},{"year":2024,"finding":"A de novo heterozygous TUBA4A variant (p.L227F) causes congenital myopathy; overexpression of the L227F mutant TUBA4A in a cellular model produced cytoplasmic protein aggregates that co-localized with ubiquitin, indicating that this mutation leads to protein misfolding and ubiquitin-positive aggregation rather than simple loss of function.","method":"Whole-exome sequencing, cellular overexpression model, immunofluorescence co-localization","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 3 — cellular model with overexpression and immunofluorescence; single lab with defined mechanistic readout (aggregation)","pmids":["38413182"],"is_preprint":false},{"year":2024,"finding":"Cultured fibroblasts from patients harboring distinct TUBA4A missense variants associated with spastic ataxia showed significant alterations in microtubule organization and dynamics, establishing that TUBA4A variants directly impair the microtubule cytoskeleton in patient-derived cells.","method":"Patient fibroblast cultures, microtubule organization/dynamics imaging","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2-3 — patient-derived cells with direct microtubule phenotype readout; three independent patient lines tested","pmids":["38884572"],"is_preprint":false},{"year":2025,"finding":"TUBA4A missense variants causing myopathy lead to TUBA4A protein accumulation detectable by immunohistochemistry in patient myofibres (positive for p62 and TDP-43 in some cases), and in vitro/in silico investigations indicate these variants cause protein abnormalities that differentially impact microtubule dynamics; domain location within TUBA4A correlates with both pattern of muscle involvement and extent of microtubule disruption.","method":"Immunohistochemical staining of muscle biopsies, in silico modeling, in vitro microtubule assays","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multicenter study with patient tissue and in vitro data; mechanistic correlation between domain location and microtubule disruption","pmids":["41678358"],"is_preprint":false},{"year":2026,"finding":"A mouse model carrying the Tuba4a p.Gln176Pro missense mutation (confirmed by CRISPR engineering) exhibits Purkinje neuron degeneration, skeletal muscle defects, and ataxia by 30 days of age with decreased lifespan, but without motor neuron degeneration; this demonstrates cell-type selective vulnerability to TUBA4A dysfunction and models human SPAX11 and CMYO26 phenotypes.","method":"ENU mutagenesis screen, CRISPR-engineered knock-in mouse, behavioral testing, neuropathology","journal":"bioRxiv : the preprint server for biology","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR-confirmed knock-in mouse with cell-type selective phenotypic readouts; preprint, not yet peer reviewed","pmids":["41889878"],"is_preprint":true},{"year":2024,"finding":"Overexpression of TUBA4A and TUBB4B in vascular smooth muscle cells (VSMCs) was shown by in vitro experiments to promote contractile-to-synthetic phenotypic switching, migration, and proliferation of VSMCs, implicating TUBA4A in cytoskeletal regulation of VSMC phenotype downstream of the GJA1-mediated PI3K/AKT/KLF4 pathway.","method":"Organoid modeling, single-cell sequencing, proteomics/RNA-seq, in vitro VSMC functional assays","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 — in vitro overexpression in VSMCs; TUBA4A not studied in isolation (co-expressed with TUBB4B); preprint only","pmids":[],"is_preprint":true}],"current_model":"TUBA4A encodes an α-tubulin isotype that is an essential structural component of the microtubule network; disease-linked mutations (particularly C-terminal ALS/FTD variants) destabilize microtubule repolymerization via dominant-negative mechanisms, while N-terminal variants cause haploinsufficiency, and TUBA4A protein levels are negatively regulated by tubulin-folding cofactor B (TBCB) downstream of miR-1825; loss of TUBA4A in vivo causes motor axonopathy with altered tubulin post-translational modifications (acetylation, detyrosination, polyglutamylation), and myopathy-associated variants drive ubiquitin-positive protein aggregation in muscle cells."},"narrative":{"teleology":[{"year":2014,"claim":"The identification of TUBA4A mutations in familial ALS families, combined with functional repolymerization assays showing these mutations destabilize microtubules, established TUBA4A as a disease gene and linked α-tubulin dysfunction to neurodegeneration.","evidence":"Exome-wide rare variant burden analysis in ALS cohorts plus microtubule repolymerization assay in patient-derived cells","pmids":["25374358"],"confidence":"High","gaps":["Mechanism by which microtubule destabilization leads to motor neuron death not defined","Whether TUBA4A mutations act via dominant-negative or loss-of-function was not resolved"]},{"year":2018,"claim":"Defining the miR-1825/TBCB/TUBA4A regulatory axis revealed that upstream TUBA4A degradation—not just coding mutations—can deplete functional α-tubulin and cause motor axon defects, broadening the pathogenic landscape beyond missense variants.","evidence":"Transcriptomic/proteomic analysis in ALS cortex tissue, TBCB overexpression studies, and zebrafish orthologue knockdown with motor axon visualization","pmids":["30030593"],"confidence":"High","gaps":["Whether miR-1825/TBCB axis is dysregulated in non-ALS neurodegenerative contexts is unknown","Direct evidence that TBCB-mediated degradation is the primary mechanism of TUBA4A loss in sporadic ALS is lacking"]},{"year":2021,"claim":"Extending TUBA4A to FTD and showing that FTD-linked variants cluster at the N-terminus with reduced protein abundance—contrasting with C-terminal ALS variants—suggested position-dependent pathogenic mechanisms for the same gene.","evidence":"Microtubule repolymerization assay and immunoblotting of FTD-associated TUBA4A variant","pmids":["34169147"],"confidence":"Medium","gaps":["Small number of FTD families studied; genotype–phenotype correlations not yet robust","Structural basis for N-terminal versus C-terminal mechanistic distinction not resolved"]},{"year":2022,"claim":"Demonstrating that an N-terminal frameshift produces no truncated protein and reduces total TUBA4A levels formalized haploinsufficiency as the mechanism for N-terminal variants, contrasting with dominant-negative effects of C-terminal mutations.","evidence":"qPCR, immunohistochemistry, and Western blotting in post-mortem brain tissue from a patient with N-terminal frameshift","pmids":["35327632"],"confidence":"Medium","gaps":["Single case study limits generalizability","Whether haploinsufficiency alone is sufficient for disease without modifier loci is unclear"]},{"year":2024,"claim":"Zebrafish loss-of-function studies with dose-dependent phenotypes rescued by human TUBA4A mRNA established a causal in vivo model and revealed that TUBA4A is required for normal tubulin post-translational modifications including acetylation, detyrosination, and polyglutamylation.","evidence":"Morpholino knockdown in zebrafish embryos with motor axon visualization, touch-evoked escape assay, and mRNA rescue","pmids":["38463699"],"confidence":"High","gaps":["Whether PTM changes are a cause or consequence of axonopathy is not resolved","Mammalian in vivo confirmation of PTM changes was not provided in this study"]},{"year":2024,"claim":"Patient fibroblast studies and the discovery of myopathy-causing TUBA4A variants expanded the phenotypic spectrum beyond neurodegeneration, showing that specific mutations drive ubiquitin-positive protein aggregation in muscle cells and directly impair microtubule organization.","evidence":"Patient fibroblast microtubule imaging (spastic ataxia), cellular overexpression with immunofluorescence co-localization (myopathy), and muscle biopsy immunohistochemistry","pmids":["38884572","38413182"],"confidence":"Medium","gaps":["Whether aggregate toxicity versus microtubule loss is the primary pathogenic insult in myopathy remains undefined","Animal model confirmation of myopathy phenotype from specific variants was not yet available from peer-reviewed sources"]},{"year":2025,"claim":"Multicenter analysis of myopathy-associated TUBA4A variants demonstrated that domain location within the protein correlates with both pattern of muscle involvement and extent of microtubule disruption, establishing a genotype–phenotype framework for TUBA4A-related myopathy.","evidence":"Immunohistochemistry of muscle biopsies (p62/TDP-43 staining), in vitro microtubule assays, and in silico modeling across multiple patient cohorts","pmids":["41678358"],"confidence":"Medium","gaps":["Precise structural mechanisms by which different domain mutations differentially affect microtubule dynamics are not resolved","Whether p62 and TDP-43 co-accumulation reflects a shared proteostatic failure or distinct pathways is unknown"]},{"year":null,"claim":"The cell-type selectivity of TUBA4A dysfunction—why certain mutations preferentially affect motor neurons, Purkinje neurons, or skeletal muscle—remains mechanistically unexplained, as does the contribution of tubulin isotype compensation and the therapeutic potential of modulating the TBCB/TUBA4A axis.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of disease-mutant TUBA4A within the αβ-tubulin heterodimer has been experimentally determined","Role of tubulin isotype compensation in modifying disease severity is unknown","Whether restoring TUBA4A levels (e.g., via miR-1825 modulation) can rescue neurodegeneration in mammalian models is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,2,4,7]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,4,7]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,2,4,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,4,7]}],"complexes":["αβ-tubulin heterodimer"],"partners":["TBCB","TUBB4B"],"other_free_text":[]},"mechanistic_narrative":"TUBA4A encodes an α-tubulin isotype that serves as an essential structural subunit of the microtubule cytoskeleton, with disease-linked mutations disrupting microtubule stability through position-dependent mechanisms. C-terminal mutations act as dominant-negative alleles that impair microtubule repolymerization, while N-terminal variants cause haploinsufficiency with reduced TUBA4A mRNA and protein [PMID:25374358, PMID:35327632]. TUBA4A protein levels are negatively regulated by tubulin-folding cofactor B (TBCB), which is itself controlled by miR-1825; loss of TUBA4A function in zebrafish causes motor axonopathy with reduced tubulin acetylation, detyrosination, and polyglutamylation, and specific missense variants cause congenital myopathy characterized by ubiquitin-positive cytoplasmic aggregates in muscle [PMID:30030593, PMID:38463699, PMID:38413182]. Mutations in TUBA4A are causative for familial ALS, FTD, spastic ataxia (SPAX11), and congenital myopathy (CMYO26) [PMID:25374358, PMID:34169147, PMID:38884572, PMID:41678358]."},"prefetch_data":{"uniprot":{"accession":"P68366","full_name":"Tubulin alpha-4A chain","aliases":["Alpha-tubulin 1","Testis-specific alpha-tubulin","Tubulin H2-alpha","Tubulin alpha-1 chain"],"length_aa":448,"mass_kda":49.9,"function":"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin","subcellular_location":"Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/P68366/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TUBA4A","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TUBA4A","total_profiled":1310},"omim":[{"mim_id":"621392","title":"CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 157; CFAP157","url":"https://www.omim.org/entry/621392"},{"mim_id":"621231","title":"OOCYTE/ZYGOTE/EMBRYO MATURATION ARREST 23; OZEMA23","url":"https://www.omim.org/entry/621231"},{"mim_id":"621226","title":"SPASTIC ATAXIA 11, AUTOSOMAL DOMINANT; SPAX11","url":"https://www.omim.org/entry/621226"},{"mim_id":"621225","title":"CONGENITAL MYOPATHY 26; CMYO26","url":"https://www.omim.org/entry/621225"},{"mim_id":"621161","title":"TUBULIN, ALPHA-1C; TUBA1C","url":"https://www.omim.org/entry/621161"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Microtubules","reliability":"Enhanced"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":345.9},{"tissue":"tongue","ntpm":249.0}],"url":"https://www.proteinatlas.org/search/TUBA4A"},"hgnc":{"alias_symbol":["FLJ30169","H2-ALPHA"],"prev_symbol":["TUBA1"]},"alphafold":{"accession":"P68366","domains":[{"cath_id":"3.40.50.1440","chopping":"1-36_47-198_387-448","consensus_level":"medium","plddt":93.1817,"start":1,"end":448}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P68366","model_url":"https://alphafold.ebi.ac.uk/files/AF-P68366-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P68366-F1-predicted_aligned_error_v6.png","plddt_mean":91.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TUBA4A","jax_strain_url":"https://www.jax.org/strain/search?query=TUBA4A"},"sequence":{"accession":"P68366","fasta_url":"https://rest.uniprot.org/uniprotkb/P68366.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P68366/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P68366"}},"corpus_meta":[{"pmid":"25374358","id":"PMC_25374358","title":"Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/25374358","citation_count":292,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28069311","id":"PMC_28069311","title":"Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28069311","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30030593","id":"PMC_30030593","title":"Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/30030593","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34169147","id":"PMC_34169147","title":"Novel TUBA4A Variant Associated With Familial Frontotemporal Dementia.","date":"2021","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34169147","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25374348","id":"PMC_25374348","title":"Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/25374348","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10645720","id":"PMC_10645720","title":"Expression of the pea (Pisum sativum L.) alpha-tubulin gene TubA1 is correlated with cell division activity.","date":"1999","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10645720","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36747013","id":"PMC_36747013","title":"In silico analysis of TUBA4A mutations in Amyotrophic Lateral Sclerosis to define mechanisms of microtubule disintegration.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36747013","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22101068","id":"PMC_22101068","title":"Behavioral and neuromorphological characterization of a novel Tuba1 mutant mouse.","date":"2011","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22101068","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33760283","id":"PMC_33760283","title":"An autopsy case of pure nigropathy with TUBA4A nonsense mutation.","date":"2021","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33760283","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26675813","id":"PMC_26675813","title":"Assessing the role of TUBA4A gene in frontotemporal degeneration.","date":"2015","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/26675813","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37418012","id":"PMC_37418012","title":"A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A.","date":"2023","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37418012","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35327632","id":"PMC_35327632","title":"Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35327632","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38884572","id":"PMC_38884572","title":"De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38884572","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7727749","id":"PMC_7727749","title":"The Pisum sativum TubA1 gene, a member of a small family of alpha-tubulin sequences.","date":"1995","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7727749","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26465396","id":"PMC_26465396","title":"TUBA4A may not be a significant genetic factor in Chinese ALS patients.","date":"2015","source":"Amyotrophic lateral sclerosis & frontotemporal degeneration","url":"https://pubmed.ncbi.nlm.nih.gov/26465396","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38413182","id":"PMC_38413182","title":"Novel TUBA4A variant causes congenital myopathy with focal myofibrillar disorganisation.","date":"2024","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38413182","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38463699","id":"PMC_38463699","title":"TUBA4A downregulation as observed in ALS post-mortem motor cortex causes ALS-related abnormalities in zebrafish.","date":"2024","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38463699","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40964866","id":"PMC_40964866","title":"TUBA4A: The Tale of an Unconventional Tubulin.","date":"2025","source":"Cytoskeleton (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/40964866","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40666348","id":"PMC_40666348","title":"Missense variants in TUBA4A cause myo-tubulinopathies.","date":"2025","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40666348","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1852622","id":"PMC_1852622","title":"Dinucleotide repeat polymorphism in the human tubulin alpha 1 (testis specific) gene (TUBA1).","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1852622","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41678358","id":"PMC_41678358","title":"Missense variants in TUBA4A cause myo-tubulinopathies.","date":"2026","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41678358","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41889878","id":"PMC_41889878","title":"A mouse model of autosomal dominant spastic ataxia and myopathy caused by a mutation in Tuba4a.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41889878","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.26.25330266","title":"Missense variants in<i>TUBA4A</i>cause myo-tubulinopathies","date":"2025-06-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.26.25330266","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.09.14.676084","title":"Cell type specific analysis of ALS-associated proteins reveals immune-regulated targets","date":"2025-09-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.14.676084","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.29.656916","title":"Reverse remodelling of the mitochondria and cytoskeleton after respiratory heart rate variability pacing of the failing sheep heart","date":"2025-05-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.29.656916","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.01.610617","title":"Organoid Modeling and Single-Cell Profiling Uncover the Migration Mechanism of Smooth Muscle Cells in Moyamoya Disease","date":"2024-09-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.01.610617","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.13.618070","title":"From Transcriptomic Signatures to Active-Site Docking and ADMET Properties Prediction: Bioinformatics-Guided Exploration of Binding Mechanisms of Cardioprotective Phytoconstituents Against Dysregulated Targets in Hypertrophic Cardiomyopathy","date":"2024-10-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.13.618070","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12024216","id":"PMC_12024216","title":"HDAC6 is a microtubule-associated deacetylase.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12024216","citation_count":2000,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12620231","id":"PMC_12620231","title":"The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12620231","citation_count":1280,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26777405","id":"PMC_26777405","title":"ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26777405","citation_count":1233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15592455","id":"PMC_15592455","title":"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.","date":"2004","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/15592455","citation_count":916,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12134159","id":"PMC_12134159","title":"CRMP-2 binds to tubulin heterodimers to promote microtubule assembly.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12134159","citation_count":636,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14630798","id":"PMC_14630798","title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630798","citation_count":616,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28302793","id":"PMC_28302793","title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28302793","citation_count":533,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18391951","id":"PMC_18391951","title":"Many sequence variants affecting diversity of adult human height.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18391951","citation_count":520,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21565611","id":"PMC_21565611","title":"Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21565611","citation_count":507,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7790358","id":"PMC_7790358","title":"Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.","date":"1995","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7790358","citation_count":427,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23463506","id":"PMC_23463506","title":"The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23463506","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15324660","id":"PMC_15324660","title":"Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization.","date":"2004","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15324660","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29656893","id":"PMC_29656893","title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29656893","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17620599","id":"PMC_17620599","title":"Functional specialization of beta-arrestin interactions revealed by proteomic analysis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17620599","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11166179","id":"PMC_11166179","title":"Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation.","date":"2001","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11166179","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14501,"output_tokens":2167,"usd":0.038004},"stage2":{"model":"claude-opus-4-6","input_tokens":5489,"output_tokens":4749,"usd":0.219255},"total_usd":0.448601,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":26971,"output_tokens":2675,"usd":0.060519},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6248,"output_tokens":2239,"usd":0.130823}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TUBA4A missense mutations destabilize the microtubule network and diminish its repolymerization capability, as demonstrated by functional analysis of ALS-associated patient variants.\",\n      \"method\": \"Microtubule repolymerization assay with ALS-associated TUBA4A mutants\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean functional assay replicated across multiple mutants, foundational paper with 292 citations\",\n      \"pmids\": [\"25374358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Excess tubulin-folding cofactor B (TBCB) leads to depolymerization and degradation of TUBA4A protein, placing TBCB as a negative regulator of TUBA4A stability; this pathway (miR-1825/TBCB/TUBA4A) is dysregulated in ALS and causes motor axon defects in vivo.\",\n      \"method\": \"Combined transcriptomic and proteomic analysis, in vivo zebrafish motor axon assay, confirmed in ALS patient brain cortex tissue\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (proteomics, transcriptomics, in vivo model, patient tissue confirmation)\",\n      \"pmids\": [\"30030593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A novel TUBA4A variant associated with familial FTD causes disrupted α-tubulin function as shown by microtubule repolymerization assay, with decreased TUBA4A protein abundance in patient brain tissue, suggesting a loss-of-function mechanism.\",\n      \"method\": \"Microtubule repolymerization assay, immunoblotting of patient brain tissue\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay in single study with patient tissue validation\",\n      \"pmids\": [\"34169147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"N-terminal frameshift mutation in TUBA4A leads to reduced total TUBA4A mRNA and protein levels without production of detectable truncated protein, suggesting haploinsufficiency as a pathogenic mechanism for N-terminal TUBA4A mutations, in contrast to C-terminal mutations which act via dominant-negative disruption of the microtubule network.\",\n      \"method\": \"qPCR, immunoblotting, immunohistochemistry of patient brain tissue\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple molecular methods on patient tissue establishing mechanistic distinction between N- and C-terminal mutations\",\n      \"pmids\": [\"35327632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Knockdown of the zebrafish TUBA4A orthologue induces motor axonopathy and disturbed motor behavior that can be rescued by human wild-type TUBA4A mRNA; additionally, loss of TUBA4A causes significant changes in post-translational modifications of tubulin including acetylation, detyrosination, and polyglutamylation.\",\n      \"method\": \"Antisense morpholino knockdown in zebrafish, rescue with human TUBA4A mRNA, antibody-based analysis of tubulin PTMs\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific phenotypic readout, rescued by wild-type mRNA, with PTM characterization\",\n      \"pmids\": [\"38463699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The L227F TUBA4A missense mutation causes formation of cytoplasmic protein aggregates that co-localize with ubiquitin in a cellular overexpression model, and immunofluorescence of patient muscle shows ubiquitin-positive TUBA4A aggregates in fibres with rimmed vacuoles, establishing a gain-of-toxic-aggregation mechanism for this variant.\",\n      \"method\": \"Cellular overexpression model with immunofluorescence, patient muscle immunofluorescence\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single study with cellular model and patient tissue, consistent mechanistic finding\",\n      \"pmids\": [\"38413182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cultured fibroblasts from patients harboring distinct TUBA4A missense variants show significant alterations in microtubule organization and dynamics, providing direct evidence for pathogenicity of ataxia-associated TUBA4A variants.\",\n      \"method\": \"Microtubule organization assay in patient-derived fibroblasts\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cellular assay in patient-derived cells, three distinct variants tested\",\n      \"pmids\": [\"38884572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Molecular dynamics simulations predict that ALS-associated TUBA4A mutations (e.g., K430N, R215C, W407X) cause structural deviations that impair GTP binding and destabilize tubulin polymerization, and that certain mutations (R320C, K430N) increase aggregation propensity of the TUBA4A protein.\",\n      \"method\": \"Molecular dynamics simulation, molecular docking (in silico)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation\",\n      \"pmids\": [\"36747013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TUBA4A missense variants associated with myopathy cause significant protein abnormalities and differentially impact microtubule dynamics; domain specificity within TUBA4A influences both the pattern of muscle involvement and the extent of microtubule disruption; immunohistochemical analysis revealed protein accumulations positive for TDP-43, p62, and TUBA4A in patient muscle biopsies.\",\n      \"method\": \"In silico and in vitro investigations of microtubule dynamics, immunohistochemistry of patient muscle biopsies\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-centre study with in vitro microtubule assays and patient tissue analysis, multiple variants\",\n      \"pmids\": [\"41678358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"A Tuba4a missense mutation (p.Gln176Pro) in mice causes Purkinje neuron degeneration and extensive skeletal muscle defects without motor neuron degeneration, establishing cell-type selective pathogenic effects of TUBA4A mutations in vivo.\",\n      \"method\": \"ENU mutagenesis screen, CRISPR-confirmed knock-in mouse model, neuropathological analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-confirmed causal mutation, defined cellular phenotype in vivo\",\n      \"pmids\": [\"41889878\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"TUBA4A encodes an α-tubulin isotype that incorporates into microtubule networks; disease-causing mutations destabilize the microtubule network (reducing repolymerization capacity), and can act through distinct mechanisms depending on variant location—C-terminal mutations cause dominant-negative microtubule disruption while N-terminal mutations cause haploinsufficiency—with TUBA4A protein stability regulated by tubulin-folding cofactor B (TBCB) downstream of miR-1825, and loss of TUBA4A additionally perturbing tubulin post-translational modifications (acetylation, detyrosination, polyglutamylation) in neurons.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TUBA4A missense mutations found in familial ALS patients destabilize the microtubule network and diminish its repolymerization capability, as demonstrated by functional microtubule repolymerization assays in patient-derived cells.\",\n      \"method\": \"Exome-wide rare variant burden analysis plus microtubule repolymerization functional assay\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay (repolymerization) with multiple ALS-linked variants; replicated in independent cohort; foundational discovery paper with 292 citations\",\n      \"pmids\": [\"25374358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Excess TBCB (tubulin-folding cofactor B), caused by downregulation of microRNA-1825, leads to depolymerization and degradation of TUBA4A protein. This miR-1825/TBCB/TUBA4A pathway was confirmed in ALS brain cortex tissue and knockdown of the TUBA4A orthologue in zebrafish caused motor axon defects, establishing TBCB as a negative regulator of TUBA4A stability.\",\n      \"method\": \"Combined transcriptomic and proteomic analysis, in vivo zebrafish knockdown, Western blotting of patient brain tissue\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (proteomics, in vivo model, patient tissue validation); identifies upstream regulatory mechanism\",\n      \"pmids\": [\"30030593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A TUBA4A variant associated with familial FTD results in decreased TUBA4A protein abundance and disrupted α-tubulin function as shown by microtubule repolymerization assay; FTD-associated variants appear more localized to the N-terminus compared to ALS variants, suggesting distinct pathogenic mechanisms.\",\n      \"method\": \"Microtubule repolymerization assay, immunoblotting, immunohistochemistry\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct repolymerization functional assay; single lab, moderate mechanistic depth\",\n      \"pmids\": [\"34169147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An N-terminal frameshift mutation in TUBA4A (p.Arg64Glyfs*90) produces no detectable truncated protein and leads to reduced total TUBA4A mRNA and protein levels, supporting haploinsufficiency as a pathogenic mechanism for N-terminal TUBA4A mutations; in contrast, C-terminal TUBA4A mutations are proposed to act via dominant-negative disruption of the microtubule network.\",\n      \"method\": \"qPCR, immunohistochemistry, Western blotting of patient brain tissue\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — patient tissue analysis with multiple molecular methods establishing mechanistic distinction between N- and C-terminal mutations; single case study\",\n      \"pmids\": [\"35327632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Knockdown of the zebrafish TUBA4A orthologue induced motor axonopathy and disturbed motor behavior in a dose-dependent manner; both phenotypes were rescued by human wild-type TUBA4A mRNA. TUBA4A loss-of-function also caused significant changes in tubulin post-translational modifications, including reduced acetylation, detyrosination, and polyglutamylation.\",\n      \"method\": \"Antisense morpholino knockdown in zebrafish embryos, motor axon visualization, touch-evoked escape response assay, mRNA rescue experiment\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with dose-dependence, mRNA rescue, and downstream PTM analysis; multiple orthogonal readouts\",\n      \"pmids\": [\"38463699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In silico molecular dynamics modeling of ALS-linked TUBA4A mutations predicts that specific mutations (e.g., K430N, R215C, W407X) impair GTP binding and tubulin polymerization, while others (R320C, K430N) significantly increase aggregation propensity of the TUBA4A α-chain, suggesting that failure to form a stable tubulin heterocomplex is a key pathogenic mechanism.\",\n      \"method\": \"Molecular dynamics simulation, molecular docking\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation\",\n      \"pmids\": [\"36747013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A de novo heterozygous TUBA4A variant (p.L227F) causes congenital myopathy; overexpression of the L227F mutant TUBA4A in a cellular model produced cytoplasmic protein aggregates that co-localized with ubiquitin, indicating that this mutation leads to protein misfolding and ubiquitin-positive aggregation rather than simple loss of function.\",\n      \"method\": \"Whole-exome sequencing, cellular overexpression model, immunofluorescence co-localization\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cellular model with overexpression and immunofluorescence; single lab with defined mechanistic readout (aggregation)\",\n      \"pmids\": [\"38413182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cultured fibroblasts from patients harboring distinct TUBA4A missense variants associated with spastic ataxia showed significant alterations in microtubule organization and dynamics, establishing that TUBA4A variants directly impair the microtubule cytoskeleton in patient-derived cells.\",\n      \"method\": \"Patient fibroblast cultures, microtubule organization/dynamics imaging\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — patient-derived cells with direct microtubule phenotype readout; three independent patient lines tested\",\n      \"pmids\": [\"38884572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TUBA4A missense variants causing myopathy lead to TUBA4A protein accumulation detectable by immunohistochemistry in patient myofibres (positive for p62 and TDP-43 in some cases), and in vitro/in silico investigations indicate these variants cause protein abnormalities that differentially impact microtubule dynamics; domain location within TUBA4A correlates with both pattern of muscle involvement and extent of microtubule disruption.\",\n      \"method\": \"Immunohistochemical staining of muscle biopsies, in silico modeling, in vitro microtubule assays\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multicenter study with patient tissue and in vitro data; mechanistic correlation between domain location and microtubule disruption\",\n      \"pmids\": [\"41678358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"A mouse model carrying the Tuba4a p.Gln176Pro missense mutation (confirmed by CRISPR engineering) exhibits Purkinje neuron degeneration, skeletal muscle defects, and ataxia by 30 days of age with decreased lifespan, but without motor neuron degeneration; this demonstrates cell-type selective vulnerability to TUBA4A dysfunction and models human SPAX11 and CMYO26 phenotypes.\",\n      \"method\": \"ENU mutagenesis screen, CRISPR-engineered knock-in mouse, behavioral testing, neuropathology\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-confirmed knock-in mouse with cell-type selective phenotypic readouts; preprint, not yet peer reviewed\",\n      \"pmids\": [\"41889878\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Overexpression of TUBA4A and TUBB4B in vascular smooth muscle cells (VSMCs) was shown by in vitro experiments to promote contractile-to-synthetic phenotypic switching, migration, and proliferation of VSMCs, implicating TUBA4A in cytoskeletal regulation of VSMC phenotype downstream of the GJA1-mediated PI3K/AKT/KLF4 pathway.\",\n      \"method\": \"Organoid modeling, single-cell sequencing, proteomics/RNA-seq, in vitro VSMC functional assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — in vitro overexpression in VSMCs; TUBA4A not studied in isolation (co-expressed with TUBB4B); preprint only\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"TUBA4A encodes an α-tubulin isotype that is an essential structural component of the microtubule network; disease-linked mutations (particularly C-terminal ALS/FTD variants) destabilize microtubule repolymerization via dominant-negative mechanisms, while N-terminal variants cause haploinsufficiency, and TUBA4A protein levels are negatively regulated by tubulin-folding cofactor B (TBCB) downstream of miR-1825; loss of TUBA4A in vivo causes motor axonopathy with altered tubulin post-translational modifications (acetylation, detyrosination, polyglutamylation), and myopathy-associated variants drive ubiquitin-positive protein aggregation in muscle cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TUBA4A encodes an α-tubulin isotype that incorporates into microtubule networks and is essential for microtubule stability, dynamics, and post-translational modification homeostasis in neurons and muscle. Disease-causing mutations destabilize microtubules and diminish repolymerization capacity, operating through variant-position–dependent mechanisms: C-terminal mutations exert dominant-negative disruption of the microtubule network, N-terminal loss-of-function mutations cause haploinsufficiency, and certain missense variants drive formation of ubiquitin-positive cytoplasmic aggregates [PMID:25374358, PMID:35327632, PMID:38413182]. TUBA4A protein stability is negatively regulated by tubulin-folding cofactor B (TBCB) in a miR-1825/TBCB/TUBA4A axis, and loss of TUBA4A perturbs tubulin acetylation, detyrosination, and polyglutamylation, linking it to motor axon integrity [PMID:30030593, PMID:38463699]. Mutations in TUBA4A cause amyotrophic lateral sclerosis, frontotemporal dementia, cerebellar ataxia, and myopathy, with domain-specific variants producing distinct patterns of neuronal and muscle pathology [PMID:25374358, PMID:34169147, PMID:38884572, PMID:41678358].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"The first functional evidence that TUBA4A is disease-relevant was established by showing that ALS-associated missense mutations destabilize the microtubule network and reduce repolymerization capacity, answering whether TUBA4A variants are pathogenic and by what cellular mechanism.\",\n      \"evidence\": \"Microtubule repolymerization assays with multiple ALS-associated TUBA4A mutants in cell models\",\n      \"pmids\": [\"25374358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which individual mutations impair polymerization at the structural level was not resolved\",\n        \"Whether different mutation positions produce distinct pathogenic mechanisms was unknown\",\n        \"In vivo consequences of TUBA4A loss or mutation were not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of the miR-1825/TBCB/TUBA4A regulatory axis established how TUBA4A protein levels are controlled post-translationally, revealing that excess TBCB drives TUBA4A depolymerization and degradation, a pathway dysregulated in ALS patient brain tissue.\",\n      \"evidence\": \"Integrated transcriptomic/proteomic analysis, zebrafish motor axon assay, and ALS patient brain cortex tissue validation\",\n      \"pmids\": [\"30030593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct binding mechanism between TBCB and TUBA4A was not structurally characterized\",\n        \"Whether TBCB-mediated degradation is selective for TUBA4A among α-tubulin isotypes was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extension of TUBA4A pathogenicity beyond ALS to frontotemporal dementia (FTD) was demonstrated when a novel variant was shown to impair microtubule repolymerization and reduce TUBA4A protein abundance in patient brain, supporting loss-of-function as a disease mechanism.\",\n      \"evidence\": \"Microtubule repolymerization assay and immunoblotting of FTD patient brain tissue\",\n      \"pmids\": [\"34169147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single family studied; broader FTD cohort replication was lacking\",\n        \"Whether reduced protein reflects degradation or impaired translation was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A mechanistic distinction between N-terminal and C-terminal TUBA4A mutations was established: N-terminal frameshift mutations cause haploinsufficiency through reduced mRNA and protein without detectable truncated product, whereas C-terminal mutations disrupt the microtubule network in a dominant-negative manner.\",\n      \"evidence\": \"qPCR, immunoblotting, and immunohistochemistry on patient brain tissue comparing N- versus C-terminal variants\",\n      \"pmids\": [\"35327632\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether nonsense-mediated decay accounts for mRNA reduction was not directly tested\",\n        \"The dominant-negative mechanism of C-terminal variants at the structural level remained unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In vivo loss-of-function studies answered whether TUBA4A is required for motor neuron function and tubulin PTM homeostasis: zebrafish TUBA4A orthologue knockdown caused motor axonopathy rescued by human wild-type mRNA, and loss of TUBA4A altered tubulin acetylation, detyrosination, and polyglutamylation, broadening the mechanistic consequences beyond simple microtubule destabilization.\",\n      \"evidence\": \"Antisense morpholino knockdown in zebrafish with human TUBA4A mRNA rescue, antibody-based tubulin PTM analysis\",\n      \"pmids\": [\"38463699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which specific PTM change is causally linked to motor axonopathy was not dissected\",\n        \"Whether PTM changes are cell-autonomous or reflect altered microtubule mass was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A gain-of-toxic-aggregation mechanism was established for the L227F variant, which forms ubiquitin-positive cytoplasmic aggregates in overexpression models and in patient muscle fibres with rimmed vacuoles, revealing a third pathogenic mode distinct from dominant-negative disruption or haploinsufficiency.\",\n      \"evidence\": \"Cellular overexpression model with immunofluorescence; patient muscle biopsy immunofluorescence\",\n      \"pmids\": [\"38413182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether aggregation is a primary pathogenic event or secondary consequence was not determined\",\n        \"Aggregation was demonstrated for a single variant; generalizability to other mutations is unknown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The disease spectrum of TUBA4A was expanded to ataxia and myopathy, with patient-derived fibroblasts and muscle biopsies showing microtubule disorganization and domain-specific patterns of muscle involvement, establishing genotype–phenotype correlations across TUBA4A variants.\",\n      \"evidence\": \"Microtubule organization assays in patient fibroblasts; immunohistochemistry of patient muscle biopsies across multiple centres and variants\",\n      \"pmids\": [\"38884572\", \"41678358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How specific TUBA4A domains map to selective tissue vulnerability remains mechanistically unresolved\",\n        \"Structural basis for domain-specific effects on microtubule dynamics is lacking\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"A mouse model carrying a Tuba4a missense mutation (Q176P) demonstrated cell-type selective vulnerability in vivo: Purkinje neuron degeneration and skeletal muscle defects occurred without motor neuron degeneration, establishing that TUBA4A mutations produce tissue-selective pathology determined by cellular context rather than uniform microtubule toxicity.\",\n      \"evidence\": \"ENU mutagenesis screen with CRISPR-confirmed knock-in mouse model and neuropathological analysis (preprint)\",\n      \"pmids\": [\"41889878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Preprint; awaits peer review\",\n        \"Why Purkinje neurons and muscle are selectively vulnerable while motor neurons are spared is unexplained\",\n        \"Whether this reflects differential α-tubulin isotype expression across cell types was not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown what determines cell-type–selective vulnerability to TUBA4A mutations across the neuronal and muscle lineages, and whether the distinct pathogenic mechanisms (dominant-negative, haploinsufficiency, toxic aggregation) converge on a shared downstream pathway or represent truly independent disease processes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural model of disease-mutant TUBA4A within the microtubule lattice exists\",\n        \"The relative contribution of TUBA4A among α-tubulin isotypes to specific cell types is uncharacterized\",\n        \"Whether tubulin PTM changes are causally pathogenic or correlative has not been determined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 4, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 4, 6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [\"microtubule\"],\n    \"partners\": [\"TBCB\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway section - it should use Reactome IDs, not GO terms. Let me reconsider.\n\n```json\n{\n  \"mechanistic_narrative\": \"TUBA4A encodes an α-tubulin isotype that incorporates into microtubule networks and is essential for microtubule stability, dynamics, and post-translational modification homeostasis in neurons and muscle. Disease-causing mutations destabilize microtubules and diminish repolymerization capacity, operating through variant-position–dependent mechanisms: C-terminal mutations exert dominant-negative disruption of the microtubule network, N-terminal loss-of-function mutations cause haploinsufficiency, and certain missense variants drive formation of ubiquitin-positive cytoplasmic aggregates [PMID:25374358, PMID:35327632, PMID:38413182]. TUBA4A protein stability is negatively regulated by tubulin-folding cofactor B (TBCB) in a miR-1825/TBCB/TUBA4A axis, and loss of TUBA4A perturbs tubulin acetylation, detyrosination, and polyglutamylation, linking it to motor axon integrity [PMID:30030593, PMID:38463699]. Mutations in TUBA4A cause amyotrophic lateral sclerosis, frontotemporal dementia, cerebellar ataxia, and myopathy, with domain-specific variants producing distinct patterns of neuronal and muscle pathology [PMID:25374358, PMID:34169147, PMID:38884572, PMID:41678358].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"The first functional evidence that TUBA4A is disease-relevant was established by showing that ALS-associated missense mutations destabilize the microtubule network and reduce repolymerization capacity, answering whether TUBA4A variants are pathogenic and by what cellular mechanism.\",\n      \"evidence\": \"Microtubule repolymerization assays with multiple ALS-associated TUBA4A mutants in cell models\",\n      \"pmids\": [\"25374358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which individual mutations impair polymerization at the structural level was not resolved\",\n        \"Whether different mutation positions produce distinct pathogenic mechanisms was unknown\",\n        \"In vivo consequences of TUBA4A loss or mutation were not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of the miR-1825/TBCB/TUBA4A regulatory axis established how TUBA4A protein levels are controlled post-translationally, revealing that excess TBCB drives TUBA4A depolymerization and degradation, a pathway dysregulated in ALS patient brain tissue.\",\n      \"evidence\": \"Integrated transcriptomic/proteomic analysis, zebrafish motor axon assay, and ALS patient brain cortex tissue validation\",\n      \"pmids\": [\"30030593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct binding mechanism between TBCB and TUBA4A was not structurally characterized\",\n        \"Whether TBCB-mediated degradation is selective for TUBA4A among α-tubulin isotypes was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extension of TUBA4A pathogenicity beyond ALS to frontotemporal dementia was demonstrated when a novel variant was shown to impair microtubule repolymerization and reduce TUBA4A protein abundance in patient brain, supporting loss-of-function as a disease mechanism.\",\n      \"evidence\": \"Microtubule repolymerization assay and immunoblotting of FTD patient brain tissue\",\n      \"pmids\": [\"34169147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single family studied; broader FTD cohort replication was lacking\",\n        \"Whether reduced protein reflects degradation or impaired translation was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A mechanistic distinction between N-terminal and C-terminal TUBA4A mutations was established: N-terminal frameshift mutations cause haploinsufficiency through reduced mRNA and protein without detectable truncated product, whereas C-terminal mutations disrupt the microtubule network in a dominant-negative manner.\",\n      \"evidence\": \"qPCR, immunoblotting, and immunohistochemistry on patient brain tissue comparing N- versus C-terminal variants\",\n      \"pmids\": [\"35327632\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether nonsense-mediated decay accounts for mRNA reduction was not directly tested\",\n        \"The dominant-negative mechanism of C-terminal variants at the structural level remained unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In vivo loss-of-function studies answered whether TUBA4A is required for motor neuron function and tubulin PTM homeostasis: zebrafish knockdown caused motor axonopathy rescued by human wild-type mRNA, and loss of TUBA4A altered tubulin acetylation, detyrosination, and polyglutamylation.\",\n      \"evidence\": \"Antisense morpholino knockdown in zebrafish with human TUBA4A mRNA rescue, antibody-based tubulin PTM analysis\",\n      \"pmids\": [\"38463699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which specific PTM change is causally linked to motor axonopathy was not dissected\",\n        \"Whether PTM changes are cell-autonomous or reflect altered microtubule mass was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A gain-of-toxic-aggregation mechanism was established for the L227F variant, which forms ubiquitin-positive cytoplasmic aggregates in cells and patient muscle, revealing a third pathogenic mode distinct from dominant-negative disruption or haploinsufficiency.\",\n      \"evidence\": \"Cellular overexpression model with immunofluorescence; patient muscle biopsy immunofluorescence\",\n      \"pmids\": [\"38413182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether aggregation is a primary pathogenic event or secondary consequence was not determined\",\n        \"Aggregation was demonstrated for a single variant; generalizability to other mutations is unknown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The disease spectrum of TUBA4A was expanded to ataxia and myopathy, with patient-derived fibroblasts and muscle biopsies showing microtubule disorganization and domain-specific patterns of tissue involvement, establishing genotype–phenotype correlations across variants.\",\n      \"evidence\": \"Microtubule organization assays in patient fibroblasts; multi-centre immunohistochemistry of patient muscle biopsies\",\n      \"pmids\": [\"38884572\", \"41678358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How specific TUBA4A domains map to selective tissue vulnerability remains mechanistically unresolved\",\n        \"Structural basis for domain-specific effects on microtubule dynamics is lacking\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"A mouse model carrying a Tuba4a missense mutation demonstrated cell-type selective vulnerability: Purkinje neuron degeneration and skeletal muscle defects occurred without motor neuron loss, establishing that TUBA4A mutations produce tissue-selective pathology.\",\n      \"evidence\": \"ENU mutagenesis screen with CRISPR-confirmed knock-in mouse model and neuropathological analysis (preprint)\",\n      \"pmids\": [\"41889878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Preprint; awaits peer review\",\n        \"Why Purkinje neurons and muscle are selectively vulnerable while motor neurons are spared is unexplained\",\n        \"Whether this reflects differential α-tubulin isotype expression across cell types was not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown what determines cell-type–selective vulnerability to TUBA4A mutations and whether the distinct pathogenic mechanisms (dominant-negative, haploinsufficiency, toxic aggregation) converge on a shared downstream pathway or represent independent disease processes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural model of disease-mutant TUBA4A within the microtubule lattice exists\",\n        \"The relative contribution of TUBA4A among α-tubulin isotypes to specific cell types is uncharacterized\",\n        \"Whether tubulin PTM changes are causally pathogenic or correlative has not been determined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 4, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 4, 6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 3, 5]}\n    ],\n    \"complexes\": [\"microtubule\"],\n    \"partners\": [\"TBCB\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TUBA4A encodes an α-tubulin isotype that serves as an essential structural subunit of the microtubule cytoskeleton, with disease-linked mutations disrupting microtubule stability through position-dependent mechanisms. C-terminal mutations act as dominant-negative alleles that impair microtubule repolymerization, while N-terminal variants cause haploinsufficiency with reduced TUBA4A mRNA and protein [PMID:25374358, PMID:35327632]. TUBA4A protein levels are negatively regulated by tubulin-folding cofactor B (TBCB), which is itself controlled by miR-1825; loss of TUBA4A function in zebrafish causes motor axonopathy with reduced tubulin acetylation, detyrosination, and polyglutamylation, and specific missense variants cause congenital myopathy characterized by ubiquitin-positive cytoplasmic aggregates in muscle [PMID:30030593, PMID:38463699, PMID:38413182]. Mutations in TUBA4A are causative for familial ALS, FTD, spastic ataxia (SPAX11), and congenital myopathy (CMYO26) [PMID:25374358, PMID:34169147, PMID:38884572, PMID:41678358].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"The identification of TUBA4A mutations in familial ALS families, combined with functional repolymerization assays showing these mutations destabilize microtubules, established TUBA4A as a disease gene and linked α-tubulin dysfunction to neurodegeneration.\",\n      \"evidence\": \"Exome-wide rare variant burden analysis in ALS cohorts plus microtubule repolymerization assay in patient-derived cells\",\n      \"pmids\": [\"25374358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which microtubule destabilization leads to motor neuron death not defined\",\n        \"Whether TUBA4A mutations act via dominant-negative or loss-of-function was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining the miR-1825/TBCB/TUBA4A regulatory axis revealed that upstream TUBA4A degradation—not just coding mutations—can deplete functional α-tubulin and cause motor axon defects, broadening the pathogenic landscape beyond missense variants.\",\n      \"evidence\": \"Transcriptomic/proteomic analysis in ALS cortex tissue, TBCB overexpression studies, and zebrafish orthologue knockdown with motor axon visualization\",\n      \"pmids\": [\"30030593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether miR-1825/TBCB axis is dysregulated in non-ALS neurodegenerative contexts is unknown\",\n        \"Direct evidence that TBCB-mediated degradation is the primary mechanism of TUBA4A loss in sporadic ALS is lacking\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extending TUBA4A to FTD and showing that FTD-linked variants cluster at the N-terminus with reduced protein abundance—contrasting with C-terminal ALS variants—suggested position-dependent pathogenic mechanisms for the same gene.\",\n      \"evidence\": \"Microtubule repolymerization assay and immunoblotting of FTD-associated TUBA4A variant\",\n      \"pmids\": [\"34169147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Small number of FTD families studied; genotype–phenotype correlations not yet robust\",\n        \"Structural basis for N-terminal versus C-terminal mechanistic distinction not resolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that an N-terminal frameshift produces no truncated protein and reduces total TUBA4A levels formalized haploinsufficiency as the mechanism for N-terminal variants, contrasting with dominant-negative effects of C-terminal mutations.\",\n      \"evidence\": \"qPCR, immunohistochemistry, and Western blotting in post-mortem brain tissue from a patient with N-terminal frameshift\",\n      \"pmids\": [\"35327632\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single case study limits generalizability\",\n        \"Whether haploinsufficiency alone is sufficient for disease without modifier loci is unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Zebrafish loss-of-function studies with dose-dependent phenotypes rescued by human TUBA4A mRNA established a causal in vivo model and revealed that TUBA4A is required for normal tubulin post-translational modifications including acetylation, detyrosination, and polyglutamylation.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish embryos with motor axon visualization, touch-evoked escape assay, and mRNA rescue\",\n      \"pmids\": [\"38463699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PTM changes are a cause or consequence of axonopathy is not resolved\",\n        \"Mammalian in vivo confirmation of PTM changes was not provided in this study\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Patient fibroblast studies and the discovery of myopathy-causing TUBA4A variants expanded the phenotypic spectrum beyond neurodegeneration, showing that specific mutations drive ubiquitin-positive protein aggregation in muscle cells and directly impair microtubule organization.\",\n      \"evidence\": \"Patient fibroblast microtubule imaging (spastic ataxia), cellular overexpression with immunofluorescence co-localization (myopathy), and muscle biopsy immunohistochemistry\",\n      \"pmids\": [\"38884572\", \"38413182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether aggregate toxicity versus microtubule loss is the primary pathogenic insult in myopathy remains undefined\",\n        \"Animal model confirmation of myopathy phenotype from specific variants was not yet available from peer-reviewed sources\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multicenter analysis of myopathy-associated TUBA4A variants demonstrated that domain location within the protein correlates with both pattern of muscle involvement and extent of microtubule disruption, establishing a genotype–phenotype framework for TUBA4A-related myopathy.\",\n      \"evidence\": \"Immunohistochemistry of muscle biopsies (p62/TDP-43 staining), in vitro microtubule assays, and in silico modeling across multiple patient cohorts\",\n      \"pmids\": [\"41678358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Precise structural mechanisms by which different domain mutations differentially affect microtubule dynamics are not resolved\",\n        \"Whether p62 and TDP-43 co-accumulation reflects a shared proteostatic failure or distinct pathways is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The cell-type selectivity of TUBA4A dysfunction—why certain mutations preferentially affect motor neurons, Purkinje neurons, or skeletal muscle—remains mechanistically unexplained, as does the contribution of tubulin isotype compensation and the therapeutic potential of modulating the TBCB/TUBA4A axis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural model of disease-mutant TUBA4A within the αβ-tubulin heterodimer has been experimentally determined\",\n        \"Role of tubulin isotype compensation in modifying disease severity is unknown\",\n        \"Whether restoring TUBA4A levels (e.g., via miR-1825 modulation) can rescue neurodegeneration in mammalian models is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 2, 4, 7]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 2, 4, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 4, 7]}\n    ],\n    \"complexes\": [\n      \"αβ-tubulin heterodimer\"\n    ],\n    \"partners\": [\n      \"TBCB\",\n      \"TUBB4B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}